Amidst the ongoing global efforts to combat coronavirus, a promising collaboration between the University of Arizona and Sunshine Biopharma is underway. This partnership aims to reduce the severity of COVID-19 infections through innovative medical technology.
The focus of their research is on protease inhibitors, which are designed to prevent the virus from replicating by inhibiting its ability to infect new cells. The research team at UA, in collaboration with Sunshine Biopharma, has developed a PLpro protease inhibitor aimed at halting the coronavirus’s replication process.
Assistant professor Rui Xiong explained the drug development stages, noting, “So, essentially, for any drug discovery campaign, it takes three stages.” The current progress is in the discovery phase, with subsequent stages involving manufacturing and clinical trials.
Rui Xiong also highlighted the potential benefits of the new molecule inhibitors for patients who might not tolerate existing treatments such as Paxlovid. This advancement could provide an alternative therapeutic option, enhancing patient care and treatment outcomes.
—
Read More Arizona News
